Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19

Jakob Malsy; Luzia Veletzky; Janna Heide; Annette Hennigs; Ines Gil-Ibanez; Alexander Stein; Marc Lütgehetmann; Ulrich Rosien; Dorothea Jasper; Sven Peine; Jens Hiller; Friedrich Haag; Stefan Schmiedel; Samuel Huber; Sabine Jordan; Marylyn M Addo; Julian Schulze Zur Wiesch

doi:10.1093/cid/ciaa1637

Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19

Jakob Malsy (Shared first author)
Luzia Veletzky (Shared first author)
Janna Heide
Annette Hennigs
Ines Gil-Ibanez
Alexander Stein
Marc Lütgehetmann
Ulrich Rosien
Dorothea Jasper
Sven Peine
Jens Hiller
Friedrich Haag
Stefan Schmiedel
Samuel Huber
Sabine Jordan
Marylyn M Addo
Julian Schulze Zur Wiesch

Related Research units

I. Medical Clinic and Polyclinic
UCCH
Institute of Medical Microbiology, Virology and Hygiene
Institute of Transfusion Medicine
Institute for Immunology

Abstract

We provide detailed clinical, virological and immunological data of a B-cell depleted patient treated with obinutuzumab for follicular lymphoma with protracted COVID-19 and viremia. A sustained response was achieved after two courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.

Bibliographical data

Original language	English
ISSN	1058-4838
DOIs	https://doi.org/10.1093/cid/ciaa1637
Publication status	Published - 26.10.2020

PubMed	33103195